SELLAS Life Sciences (SLS) Gains from Investment Securities (2010 - 2023)
SELLAS Life Sciences (SLS) reported Gains from Investment Securities of $368000.0 for Q4 2023, down 18.04% on a QoQ basis from $449000.0 in Q1 2022.
SELLAS Life Sciences (SLS) has 10 years of Gains from Investment Securities data on file, last reported at $368000.0 in Q4 2023.
- Quarterly Gains from Investment Securities changed N/A year-over-year to $368000.0 in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $368000.0 (down 18.04% YoY) and the FY2025 annual result came in at $526000.0, up 721.88% from the prior year.
- Gains from Investment Securities eased to $368000.0 in Q4 2023 per SLS's latest filing, from $449000.0 in the prior quarter.
- Across five years, Gains from Investment Securities topped out at $853000.0 in Q2 2020 and bottomed at -$1000.0 in Q4 2019.
- The 4-year median for Gains from Investment Securities is $408500.0 (2022), against an average of $390333.3.
- Peak annual rise in Gains from Investment Securities reached 55.09% in 2020, while the deepest fall reached 55.09% in 2020.
- Tracing SLS's Gains from Investment Securities over 4 years: stood at -$1000.0 in 2019, then surged by 85400.0% to $853000.0 in 2020, then tumbled by 47.36% to $449000.0 in 2022, then retreated by 18.04% to $368000.0 in 2023.
- Per Business Quant, the three latest SLS Gains from Investment Securities figures stand at $368000.0 (Q4 2023), $449000.0 (Q1 2022), and $853000.0 (Q2 2020).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | SELLAS Life Sciences | 1.61 Bn | 1.61 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 368,000.00 |
| Dec 31, 2023 | 368,000.00 |
| Mar 31, 2022 | 449,000.00 |
| Mar 31, 2022 | 449,000.00 |
| Jun 30, 2020 | 853,000.00 |
| Jun 30, 2020 | 853,000.00 |
| Mar 31, 2020 | 123,000.00 |
| Mar 31, 2020 | 123,000.00 |
| Dec 31, 2019 | -1,000.00 |
| Dec 31, 2019 | -1,000.00 |
| Jun 30, 2019 | 550,000.00 |
| Jun 30, 2019 | 550,000.00 |
| Dec 31, 2017 | 10,000.00 |
| Dec 31, 2017 | 10,000.00 |
| Dec 31, 2016 | 55,000.00 |
| Dec 31, 2016 | 55,000.00 |
| Mar 31, 2013 | 393,101.00 |
| Mar 31, 2013 | 393,101.00 |
| Dec 31, 2012 | 264,816.00 |
| Dec 31, 2012 | 264,816.00 |
| Sep 30, 2012 | 1.65 Mn |
| Sep 30, 2012 | 1.65 Mn |
| Jun 30, 2012 | 39,219.00 |
| Jun 30, 2012 | 39,219.00 |
| Dec 31, 2011 | 3.32 Mn |
| Dec 31, 2011 | 3.32 Mn |
| Dec 31, 2010 | 4.33 Mn |
| Dec 31, 2010 | 4.33 Mn |